Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: methacrylic acid - ethyl acrylate copolymer (1:1); povidone; glyceryl monostearate; light magnesium oxide; silicon dioxide; microcrystalline cellulose; crospovidone; macrogol 400; macrogol 6000; purified talc; polysorbate 80; iron oxide red; hypromellose phthalate; pregelatinised maize starch; hyprolose; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole sps is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

jubilant pharma australia pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg - tablet, enteric coated - excipient ingredients: hypromellose phthalate; microcrystalline cellulose; hyprolose; purified talc; crospovidone; macrogol 6000; glyceryl monostearate; methacrylic acid - ethyl acrylate copolymer (1:1); light magnesium oxide; pregelatinised maize starch; povidone; iron oxide red; macrogol 400; silicon dioxide; polysorbate 80; titanium dioxide; hypromellose; iron oxide yellow; maize starch; sucrose - esomeprazole jgl is indicated for: gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti- inflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv (available in other brands) solution by intravenous infusion. pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of duodenal ulcer associated with helicobacter pylori ? eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

sun pharma anz pty ltd - esomeprazole magnesium, quantity: 20.7 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hyprolose; sodium stearylfumarate; hypromellose phthalate; macrogol 6000; diethyl phthalate; crospovidone; macrogol 400; microcrystalline cellulose; povidone; macrogol 4000; purified talc; titanium dioxide; hypromellose; iron oxide red; maize starch; sucrose - gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: iron oxide red; hyprolose; povidone; microcrystalline cellulose; silicon dioxide; crospovidone; polysorbate 80; maize starch; hypromellose phthalate; pregelatinised maize starch; light magnesium oxide; sucrose; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; glyceryl monostearate; macrogol 6000; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hypromellose phthalate; maize starch; glyceryl monostearate; sucrose; iron oxide red; hyprolose; macrogol 6000; silicon dioxide; povidone; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1); light magnesium oxide; microcrystalline cellulose; crospovidone; purified talc; pregelatinised maize starch; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; light magnesium oxide; crospovidone; sucrose; glyceryl monostearate; iron oxide red; methacrylic acid - ethyl acrylate copolymer (1:1); maize starch; macrogol 6000; povidone; polysorbate 80; pregelatinised maize starch; purified talc; silicon dioxide; hypromellose phthalate; hyprolose; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: iron oxide red; hyprolose; povidone; microcrystalline cellulose; silicon dioxide; crospovidone; polysorbate 80; maize starch; hypromellose phthalate; pregelatinised maize starch; light magnesium oxide; sucrose; methacrylic acid - ethyl acrylate copolymer (1:1); purified talc; glyceryl monostearate; macrogol 6000; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: microcrystalline cellulose; light magnesium oxide; crospovidone; sucrose; glyceryl monostearate; iron oxide red; methacrylic acid - ethyl acrylate copolymer (1:1); maize starch; macrogol 6000; povidone; polysorbate 80; pregelatinised maize starch; purified talc; silicon dioxide; hypromellose phthalate; hyprolose; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - English - Department of Health (Therapeutic Goods Administration)

generic partners pty ltd - esomeprazole magnesium trihydrate, quantity: 22.264 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hypromellose phthalate; maize starch; glyceryl monostearate; sucrose; iron oxide red; hyprolose; macrogol 6000; silicon dioxide; povidone; polysorbate 80; methacrylic acid - ethyl acrylate copolymer (1:1); light magnesium oxide; microcrystalline cellulose; crospovidone; purified talc; pregelatinised maize starch; macrogol 400; titanium dioxide; hypromellose; iron oxide yellow - gastro-oesophageal reflux disease (gord). ? treatment of erosive reflux oesophagitis ? long-term management of patients with healed oesophagitis to prevent relapse ? symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy. ? short-term treatment of upper gastrointestinal symptoms associated with non-steroidal antiinflammatory drug nsaid (non-selective and cox-2 selective) therapy. ? healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (nonselective and cox-2 selective) therapy. ? prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk.,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole iv solution by intravenous infusion.,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion.,in combination with appropriate antibiotics for: ? healing of

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - esomeprazole magnesium, quantity: 20.7 mg (equivalent: esomeprazole, qty 20 mg) - tablet, enteric coated - excipient ingredients: hypromellose phthalate; macrogol 4000; crospovidone; macrogol 6000; macrogol 400; microcrystalline cellulose; sodium stearylfumarate; hyprolose; diethyl phthalate; purified talc; povidone; titanium dioxide; hypromellose; iron oxide red; maize starch; sucrose - gastro-oesophageal reflux disease (gord),- treatment of erosive reflux oesophagitis,- long-term management of patients with healed oesophagitis to prevent relapse,- symptomatic treatment of gastro-oesophageal reflux disease (gord),patients requiring nsaid therapy,- short-term treatment of upper gastrointestinal symptoms associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- healing of gastric ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy,- prevention of gastric and duodenal ulcers associated with non-steroidal anti-inflammatory drug nsaid (non-selective and cox-2 selective) therapy in patients at risk,prevention of rebleeding of gastric or duodenal ulcers following treatment with esomeprazole solution administered by intravenous infusion,pathological hypersecretory conditions including zollinger-ellison syndrome and idiopathic hypersecretion,in combination with appropriate antibiotics for:,- healing of duodenal ulcer associated with helicobacter pylori,- eradication of helicobacter pylori in patients with active or healed peptic ulcer